Fly News Breaks for February 27, 2020
Feb 27, 2020 | 07:11 EDT
Barclays analyst Carter Gould initiated coverage of Biogen with an Overweight rating and $389 price target. Performance this year will be dictated by aducanumab approval in Alzheimer's disease, said Gould, who expects approval and argues that the risk/reward is "skewed positively" given what he sees as negativity from investors around the Alzheimer's program. Gould initiated coverage of the U.S. Biopharmaceuticals industry with a Positive view citing waning near-term concerns on drug pricing reform, evidence of innovation and attractive valuations.
News For BIIB From the Last 2 Days
There are no results for your query BIIB